A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match patients to the combination.
Latest Information Update: 20 Dec 2023
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary) ; Palbociclib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms SPRING
- 24 Jan 2023 Status changed from active, no longer recruiting to discontinued.
- 25 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology